Open Medicine EU

Archives for

The Report on Clinical Trials agreed yesterday in the ENVI Committee would bring more transparency than before, but less than was originally proposed by the Rapporteur, Glenis Wilmott. She had proposed the publication of a Clinical Study Report within one year of the completion or termination of a trial. The compromise agreed a two stage… » read more

Posted by Jim Murray

The proposal for the revision of the Clinical Trials Directive will be discussed tomorrow (29th May) in the Envi Committee of the European Parliament. On transparency and disclosure of trial results I am not hearing good news. The rapporteur, Glenis Wilmott, made a good proposal in her report – for the publication of a Clinical… » read more

Posted by Jim Murray

Like AbbVie, described in my last post, a second American company, InterMune, has taken legal action to prevent or restrict the European Medicines Agency from disclosing certain clinical trial data after a medicine is approved for marketing. On 4th March a federal appeals court upheld the conviction of the former chief executive of InterMune, W.… » read more

Posted by Jim Murray

Two American pharmaceutical companies, AbbVie and Intermune, have taken legal action to prevent or restrict the European Medicines Agency from disclosing certain clinical trial data after a medicine is approved for marketing. In my opinion, both companies have been involved in activities that seem to prove the need for more transparency and not less. AbbVie… » read more

Posted by Jim Murray